For the quarter ending 2025-09-30, ACRV had -$6,489K decrease in cash & cash equivalents over the period. -$13,182K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,234 | -40,686 |
| Depreciation expense | 349 | 646 |
| Stock-based compensation expense | 3,911 | 7,718 |
| Non-cash operating lease expense | 259 | 503 |
| Net amortization of premiums and accretion of discounts on investments | 34 | 533 |
| Prepaid expenses and other current assets | 223 | -1,169 |
| Accounts payable | -9 | 264 |
| Accrued expenses and other current liabilities | 1,972 | -4,844 |
| Operating lease liabilities | -274 | -382 |
| Net cash used in operating activities | -12,283 | -36,145 |
| Purchases of investments | 33,190 | 35,284 |
| Proceeds from maturities of investments | 40,000 | 74,500 |
| Purchases of property and equipment | 899 | 551 |
| Net cash provided by (used in) investing activities | 5,911 | 38,665 |
| Proceeds from exercise of stock options | 0 | 1 |
| Payments of tax withholdings related to vesting of restricted stock units | 117 | 441 |
| Net cash (used in) provided by financing activities | -117 | -440 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -6,489 | 2,080 |
| Cash and cash equivalents at beginning of period | 40,016 | - |
| Cash and cash equivalents at end of period | 35,607 | - |
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)